Journal Scans
Overall Survival With Cisplatin–Gemcitabine and Bevacizumab or Placebo as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: Results From a Randomised Phase III Trial (AVAiL)
Bevacizumab Lengthens PFs, but not OS, in Advanced NSCLC
M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, N Leighl, J Mezger, V Archer, N Moore, C Manegold, BO17704 Study Group
20100801
2010 Sept 1
Ann Oncol
Overall Survival With Cisplatin–Gemcitabine and Bevacizumab or Placebo as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: Results From a Randomised Phase III Trial (AVAiL)
Ann Oncol. 2010 Sept 1;21(9):1804-1809, M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, N Leighl, J Mezger, V Archer, N Moore, C Manegold, BO17704 Study Group
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
In two phase III trials (E4599 and AVAiL), adding bevacizumab to chemotherapy significantly improved progression-free survival (PFS) in patients with advanced nonsquamous non–small-cell lung cancer (NSCLC). The Eastern Cooperative Oncology Group E4599 study also showed a significant improvement in overall survival (OS) with the addition of bevacizumab. Now, Reck et al report the final OS analysis of the European AVAiL trial. In the AVAil study, 1043 patients were randomized to receive cisplatin/gemcitabine...
